Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (SURPASS-2)

In by ECIR

Locations
Lake CIty
Condition
Diabetes

Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (SURPASS-2)

  • This field is for validation purposes and should be left unchanged.
clinicaltrials.gov

Eligibility

Inclusion Criteria

– Diagnosed with type 2 diabetes mellitus
– HbA1c between 7.0% and 10.5%
– Currently on stable treatment with metformin
– Body mass index (BMI) of at least 25

Exclusion Criteria

– Currently taking any other diabetes medication other than metformin
– Have had chronic or acute pancreatitis
– Have proliferative diabetic retinopathy or diabetic maculopathy or acute nonproliferative
diabetic retinopathy
– Have disorders associated with slowed emptying of the stomach, or have had any stomach
surgeries for the purpose of weight loss
– Have acute or chronic hepatitis
– Have an eGFR <45 ml/min - Currently taking weight loss drugs, including over-the-counter medications

Back to Current Studies